Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009-2019

• প্রধান লেখক: Manuel García-Goñi (লেখক), Isabel Río-Álvarez (লেখক), David Carcedo (লেখক), Alba Villacampa (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: MDPI AG, 2021-04-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Since the first biosimilar medicine, Omnitrope^® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System (NHS) over the period betw...